Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies

31 Jul 2024

Abstract excerpt

CD38 is a metabolically active enzyme broadly expressed on the surface of normal and malignant hematologic cells. It has been targeted clinically with anti-CD38 mAbs, for which efficacy may be limited by NK cell fratricide. Isatuximab is an anti-CD38 mAb that uniquely inhibits CD38 metabolic activity. Here, we used CRISPR/AAV to generate fratricide-resistant and metabolically-enhanced CD38KO/CD38-CAR NK cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Hematopoietic Stem Cell Transplantation
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40552130
DOI: 10.1016/j.bneo.2024.100032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignanciesPMID 40552130Read ↗

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK CellsSemantic proximity Read ↗

Off-the-shelf allogeneic polyclonal CD38KO/CD38-CAR γδT cells for the treatment of T cell malignanciesSemantic proximity Read ↗

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer ImmunotherapySemantic proximity Read ↗

CRISPR-Targeted CAR Gene Insertion Using Cas9/RNP and AAV6 Enhances Anti-AML Activity of Primary NK CellsSemantic proximity Read ↗

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer ImmunotherapySemantic proximity Read ↗

Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.Semantic proximity Read ↗

Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies.Semantic proximity Read ↗

Leveraging IFNγ/CD38 regulation to unmask and target leukemia stem cells in acute myelogenous leukemiaSemantic proximity Read ↗

Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor ActivitySemantic proximity Read ↗

The high-performance technology CRISPR/Cas9 improves knowledge and management of acute myeloid leukemia.Semantic proximity Read ↗

Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potencySemantic proximity Read ↗

Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 RibonucleoproteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.